Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (17)

Search Parameters:
Keywords = gebbia

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 556 KiB  
Article
Added Value of SPECT/CT in Radio-Guided Occult Localization (ROLL) of Non-Palpable Pulmonary Nodules Treated with Uniportal Video-Assisted Thoracoscopy
by Demetrio Aricò, Lucia Motta, Giulia Giacoppo, Michelangelo Bambaci, Paolo Macrì, Stefania Maria, Francesco Barbagallo, Nicola Ricottone, Lorenza Marino, Gianmarco Motta, Giorgia Leone, Carlo Carnaghi, Vittorio Gebbia, Domenica Caponnetto and Laura Evangelista
J. Clin. Med. 2025, 14(15), 5337; https://doi.org/10.3390/jcm14155337 - 29 Jul 2025
Viewed by 246
Abstract
Background/Objectives: The extensive use of computed tomography (CT) has led to a significant increase in the detection of small and non-palpable pulmonary nodules, necessitating the use of invasive methods for definitive diagnosis. Video-assisted thoracoscopic surgery (VATS) has become the preferred procedure for nodule [...] Read more.
Background/Objectives: The extensive use of computed tomography (CT) has led to a significant increase in the detection of small and non-palpable pulmonary nodules, necessitating the use of invasive methods for definitive diagnosis. Video-assisted thoracoscopic surgery (VATS) has become the preferred procedure for nodule resections; however, intraoperative localization remains challenging, especially for deep or subsolid lesions. This study explores whether SPECT/CT improves the technical and clinical outcomes of radio-guided occult lesion localization (ROLL) before uniportal video-assisted thoracoscopic surgery (u-VATS). Methods: This is a retrospective study involving consecutive patients referred for the resection of pulmonary nodules who underwent CT-guided ROLL followed by u-VATS between September 2017 and December 2024. From January 2023, SPECT/CT was systematically added after planar imaging. The cohort was divided into a planar group and a planar + SPECT/CT group. The inclusion criteria involved nodules sized ≤ 2 cm, with ground glass or solid characteristics, located at a depth of <6 cm from the pleural surface. 99mTc-MAA injected activity, timing, the classification of planar and SPECT/CT image findings (focal uptake, multisite with focal uptake, multisite without focal uptake), spillage, and post-procedure complications were evaluated. Statistical analysis was performed, with continuous data expressed as the median and categorical data as the number. Comparisons were made using chi-square tests for categorical variables and the Mann–Whitney U test for procedural duration. Cohen’s kappa coefficient was calculated to assess agreement between imaging modalities. Results: In total, 125 patients were selected for CT-guided radiotracer injection followed by uniportal-VATS. The planar group and planar + SPECT/CT group comprised 60 and 65 patients, respectively. Focal uptake was detected in 68 (54%), multisite with focal uptake in 46 (36.8%), and multisite without focal uptake in 11 patients (8.8%). In comparative analyses between planar and SPECT/CT imaging in 65 patients, 91% exhibited focal uptake, revealing significant differences in classification for 40% of the patients. SPECT/CT corrected the classification of 23 patients initially categorized as multisite with focal uptake to focal uptake, improving localization accuracy. The mean procedure duration was 39 min with SPECT/CT. Pneumothorax was more frequently detected with SPECT/CT (43% vs. 1.6%). The intraoperative localization success rate was 96%. Conclusions: SPECT/CT imaging in the ROLL procedure for detecting pulmonary nodules before u-VATs demonstrates a significant advantage in reclassifying radiotracer positioning compared to planar imaging. Considering its limited impact on surgical success rates and additional procedural time, SPECT/CT should be reserved for technically challenging cases. Larger sample sizes, multicentric and prospective randomized studies, and formal cost–utility analyses are warranted. Full article
(This article belongs to the Section Nuclear Medicine & Radiology)
Show Figures

Figure 1

21 pages, 703 KiB  
Review
A Practical Narrative Review on the Role of Magnesium in Cancer Therapy
by Daniela Sambataro, Giuseppina Scandurra, Linda Scarpello, Vittorio Gebbia, Ligia J. Dominguez and Maria Rosaria Valerio
Nutrients 2025, 17(14), 2272; https://doi.org/10.3390/nu17142272 - 9 Jul 2025
Viewed by 872
Abstract
Magnesium (Mg2+) has gained oncologists’ attention due to its wide range of biological functions and frequent use as a complementary or integrative agent. This review outlines Mg’s actions, its complex role in carcinogenesis and tumor risk, and clinical issues. Mg2+ [...] Read more.
Magnesium (Mg2+) has gained oncologists’ attention due to its wide range of biological functions and frequent use as a complementary or integrative agent. This review outlines Mg’s actions, its complex role in carcinogenesis and tumor risk, and clinical issues. Mg2+ is essential in numerous biochemical processes, including adenosine triphosphate production, cellular signal transduction, DNA, RNA and protein synthesis, and bone formation. Pertinent full-text articles were thoroughly examined, and the most relevant ones were selected for inclusion in this review. There is conflicting scientific evidence about the relationship between Mg2+ changes and cancer risk, apart from colorectal cancer. Chronic Mg2+ deficiency leads to immune dysfunctions and enhanced baseline inflammation associated with oxidative stress related to various age-associated morbidities and cancer. On the other hand, Mg2+ deficiency is associated with drug or chemotherapy-related hypomagnesemia, postoperative pain, cachexia, opioid-induced constipation, normal tissue protection from radiation damage, and prevention of nephrotoxicity. A balanced diet usually provides sufficient Mg2+, but supplementation may be necessary in some clinical settings. Full article
(This article belongs to the Section Clinical Nutrition)
Show Figures

Figure 1

11 pages, 1481 KiB  
Article
Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study
by Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Maria Vita Sanò, Angela Prestifilippo, Antonio Russo, Vittorio Gebbia, Livio Blasi, Dario Giuffrida, Giuseppa Scandurra, Antonio Savarino, Alfredo Butera, Nicolò Borsellino, Francesco Verderame, Michele Caruso and Vincenzo Adamo
Cancers 2025, 17(13), 2069; https://doi.org/10.3390/cancers17132069 - 20 Jun 2025
Viewed by 507
Abstract
Background: Older women represent a significant and increasing population of patients with breast cancer, accounting for over 40% of new cases of breast cancer. However, this growing subgroup of patients is still underrepresented in clinical trials, and treatment is usually selected based [...] Read more.
Background: Older women represent a significant and increasing population of patients with breast cancer, accounting for over 40% of new cases of breast cancer. However, this growing subgroup of patients is still underrepresented in clinical trials, and treatment is usually selected based on limited data from retrospective subgroup analyses. However, the ESMO guidelines for metastatic breast cancer (mBC) suggest that the management decision should not be based on age alone. Nab-paclitaxel (nab-P) was associated with improved efficacy and a better safety profile than solvent-based taxanes without steroid or antihistamine premedication, making this treatment appealing to elderly patients. Patients and methods: This is an observational, retrospective, multicenter study, evaluating the safety and activity of nab-paclitaxel (nab-P) in elderly patients (≥65 years old) with HER2-negative mBC from 11 Sicilian oncology centers. The primary endpoint of the study was the safety nab-P in elderly mBC patients; secondary endpoints included the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: We included 70 patients, and all were evaluable for safety and efficacy. All patients had previously been pretreated with taxane-based chemotherapy in a (neo)-adjuvant or metastatic setting. One third of the patients received nab-P as a fourth line therapy. Most of the patients were treated with nab-P at doses of 260 mg/m2 3-weekly (87.1%), and 12.9% received a nab-P dose of 125 mg/m2 weekly. Patients’ characteristics included a median age of 67 years (range 65–83 years), a median ECOG PS of 1 (range 0–2), and the following intrinsic molecular subtypes: Luminal A (18.8%), Luminal B HER-2 negative (62.5%), and triple negative (18.8%). Nab-P was administered for a median of six cycles (range 1–21), with 35.5% of patients experiencing a dose reduction, and 11.5% treatment discontinuation due to toxicity. Adverse events were mainly G2-G3 and occurred mostly in patients treated with 3-weekly nab-P (85.7%). The ORR was 31.3% (CR in 6.3% and PR in 25% of pts) and the DCR was 70.4%. Median PFS was 6 months (95% CI, 2–38), and median OS was 40.5 months (95% CI, 7–255). Conclusions: Our real-life study showed that nab-P is an effective, well-tolerated regimen in elderly mBC patients, including taxane-pretreated patients, and can be safely administered in elderly mBC patients. Full article
(This article belongs to the Special Issue Molecular Pathology and Human Cancers)
Show Figures

Figure 1

16 pages, 1063 KiB  
Systematic Review
Combined Neuroendocrine Carcinoma and Hepatocellular Carcinoma of the Liver: Systematic Literature Review Suggests Implementing Biological Characterization to Optimize Therapeutic Strategy
by Daniela Sambataro, Sandro Bellavia, Paolo Di Mattia, Danilo Centonze, Carmela Emmanuele, Annalisa Bonasera, Giuseppe Caputo, Andrea Maria Onofrio Quattrocchi, Ernesto Vinci, Vittorio Gebbia and Maria Rosaria Valerio
Cancers 2025, 17(7), 1074; https://doi.org/10.3390/cancers17071074 - 22 Mar 2025
Viewed by 729
Abstract
Background: Mixed neuroendocrine–non-neuroendocrine tumors (MINEN) of the liver are exceptionally rare, with limited data available regarding their clinical behavior, pathogenesis, and optimal management. The coexistence of hepatocellular carcinoma (HCC) and neuroendocrine carcinoma (NEC) within the liver presents diagnostic and therapeutic challenges. Methods: A [...] Read more.
Background: Mixed neuroendocrine–non-neuroendocrine tumors (MINEN) of the liver are exceptionally rare, with limited data available regarding their clinical behavior, pathogenesis, and optimal management. The coexistence of hepatocellular carcinoma (HCC) and neuroendocrine carcinoma (NEC) within the liver presents diagnostic and therapeutic challenges. Methods: A systematic literature search was conducted on PubMed, identifying cases of primary mixed HCC and NEC in the liver. The search adhered to PRISMA guidelines, and relevant studies were critically analyzed. A total of 45 documented cases were reviewed, focusing on patient demographics, clinical characteristics, treatment strategies, and outcomes. Results: Most patients (90%) were male, with a median age of 66.5 years. Hepatitis B or C infection was present in 74% of cases, and liver cirrhosis was reported in 38%. The combined type was the most frequently observed histological pattern (65%). Treatment modalities varied, including transarterial chemoembolization (TACE), radiofrequency ablation (RFA), surgery, and systemic therapies. The median overall survival was 10 months, highlighting the aggressive nature of these tumors. Conclusions: Given the rarity and poor prognosis of hepatic MINEN tumors, multidisciplinary management is essential. Advanced molecular profiling may offer insights into tumor biology and potential therapeutic targets. Future research should explore novel systemic therapies, including immune checkpoint inhibitors, to improve patient outcomes. Full article
(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
Show Figures

Figure 1

12 pages, 1636 KiB  
Article
Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer
by Maria Rosaria Valerio, Federica Martorana, Maria Vita Sanò, Daniela Sambataro, Gianmarco Motta, Lucia Motta, Giuliana Pavone, Vittorio Gebbia and Giuseppa Scandurra
Biomedicines 2025, 13(3), 546; https://doi.org/10.3390/biomedicines13030546 - 21 Feb 2025
Cited by 2 | Viewed by 1412
Abstract
Background: Adherence to oral anticancer therapies among breast cancer patients is an often-overlooked issue. A lack of patient compliance can be caused by several factors, and may hinder the efficacy of prescribed medication, leading to a shorter than expected survival. In this context, [...] Read more.
Background: Adherence to oral anticancer therapies among breast cancer patients is an often-overlooked issue. A lack of patient compliance can be caused by several factors, and may hinder the efficacy of prescribed medication, leading to a shorter than expected survival. In this context, few data about adherence to CDK4/6 inhibitors in real-world practice are available. We report here the results of a retrospective analysis of adherence to abemaciclib plus endocrine therapy in a cohort of women with hormone receptor-positive (HR+), epidermal growth factor 2 negative (HER2−) breast cancer. Methods: Abemaciclib adherence was computed as the ratio between the total number of cycles/months that medication was supplied and the months between the first and the last prescription. The proportion of Days Covered (PDC) ranged from 0 to 1. A score of 0.8 (i.e., 80% adherence rate) was the cutoff used to classify the patients as adherent (0.8 ≤ PDC ≤ 1) or non-adherent (0 ≤ PDC < 0.8). The received dose intensity was also calculated. Results: The abemaciclib pharmacy claims of 100 women with HR+/HER2− breast cancer were retrieved. Most patients (91%) were treated in the advanced setting. Abemaciclib was more frequently taken with an aromatase inhibitor (63%) than with fulvestrant (27%). In this population, the adherence rate was high (92.25% + 1.939 SD). The proportion of non-adherent patients taking abemaciclib with PDC <0.8 was 12%. There was a significative correlation between the occurrence of side effects and the use of <5 drugs for non-oncological illnesses, probably reflecting concomitant non-oncological diseases. Conclusions: Adherence to abemaciclib-based therapy is high in a real-life setting, pending the adequate and proactive management of patients. The careful evaluation of patients and detailed information about expected adverse events are essential to ensure adherence to this antineoplastic agent. Full article
(This article belongs to the Special Issue Drug Resistance and Novel Targets for Cancer Therapy—Second Edition)
Show Figures

Figure 1

33 pages, 1269 KiB  
Systematic Review
Brain Metastasis in Endometrial Cancer: A Systematic Review
by Daniela Sambataro, Vittorio Gebbia, Annalisa Bonasera, Andrea Maria Onofrio Quattrocchi, Giuseppe Caputo, Ernesto Vinci, Paolo Di Mattia, Salvatore Lavalle, Basilio Pecorino, Giuseppa Scandurra, Giuseppe Scibilia, Danilo Centonze and Maria Rosaria Valerio
Cancers 2025, 17(3), 402; https://doi.org/10.3390/cancers17030402 - 25 Jan 2025
Viewed by 2093
Abstract
Background: Brain metastases (BMs) from endometrial cancer (EC) are rare and challenging to treat, with limited standardized guidelines. This systematic review aims to evaluate the incidence, therapeutic strategies, and outcomes associated with brain metastases in EC patients, offering insights for clinical practice and [...] Read more.
Background: Brain metastases (BMs) from endometrial cancer (EC) are rare and challenging to treat, with limited standardized guidelines. This systematic review aims to evaluate the incidence, therapeutic strategies, and outcomes associated with brain metastases in EC patients, offering insights for clinical practice and future research. Methods: A comprehensive literature search was conducted using PRISMA guidelines, including PUBMED up to October 2024. Reports reporting individual or aggregate data on EC brain metastases were included. Descriptive and quantitative analyses were performed on incidence, treatment modalities, and survival outcomes. Three reports that used data from the Surveillance, Epidemiology, and End Results and National Cancer Database were used only to assess the incidence of brain metastases from endometrial carcinoma. Results: From 911 reports identified, we included 99 reports, identifying 594 cases; these and the case of a patient with brain metastasis from endometrial carcinoma followed at our center were used for analysis of disease characteristics; incidence; and treatment modalities, such as surgery, radiotherapy, chemotherapy, and combinations. Survival outcomes were influenced by treatment type and disease characteristics, with multimodal approaches showing improved outcomes. Discussion: This review underscores the rarity of EC brain metastases and highlights the need for tailored, multimodal treatment strategies. Future research should focus on prospective trials and molecular profiling to optimize management. Full article
(This article belongs to the Special Issue “Cancer Metastasis” in 2023–2024)
Show Figures

Figure 1

16 pages, 1629 KiB  
Systematic Review
The Effect of Endometriosis on In Vitro Fertilization Outcomes: A Systematic Review and Meta-Analysis
by Ilenia Mappa, Zoe Pauline Page, Daniele Di Mascio, Chiara Patelli, Francesco D’Antonio, Antonella Giancotti, Francesco Gebbia, Giulia Mariani, Mauro Cozzolino, Ludovico Muzii and Giuseppe Rizzo
Healthcare 2024, 12(23), 2435; https://doi.org/10.3390/healthcare12232435 - 3 Dec 2024
Cited by 2 | Viewed by 2809
Abstract
Objectives: The purpose of this study was to evaluate the impact of endometriosis on various outcomes of in vitro fertilization (IVF), including live birth rates, clinical pregnancy rates, fertilization rates, and implantation rates, through a systematic review and meta-analysis. Methods: Systematic searches were [...] Read more.
Objectives: The purpose of this study was to evaluate the impact of endometriosis on various outcomes of in vitro fertilization (IVF), including live birth rates, clinical pregnancy rates, fertilization rates, and implantation rates, through a systematic review and meta-analysis. Methods: Systematic searches were carried out using PubMed, MEDLINE, Cochrane Central Register of Controlled Trials, Scopus, EMBASE, and Web of Science from January 2010 to November 2023. Studies comparing IVF outcomes in women with and without endometriosis were included. The primary outcome was live birth rate; secondary outcomes included clinical pregnancy, fertilization, and implantation rates. Data were extracted and analyzed using odds ratio (OR) and 95% confidence interval (CI) with fixed or random-effects models, depending on heterogeneity. Results: From 1340 studies initially identified, 40 studies met the inclusion criteria, encompassing 8970 women with endometriosis and 42,946 control participants. There were no significant differences between the endometriosis and control groups in terms of live birth rate (OR 1.03, 95% CI 0.75–1.41, p = 0.84), clinical pregnancy rate (OR 0.86, 95% CI 0.72–1.02, p = 0.1), or fertilization rate (OR 0.96, 95% CI 0.79–1.15, p = 0.64). However, endometriosis was associated with a significantly lower implantation rate (OR 0.85, 95% CI 0.74–0.97, p = 0.02). Conclusions: Endometriosis significantly negatively affects implantation rates in women undergoing IVF, despite the absence of significant differences in live birth, clinical pregnancy, and fertilization rates. Further research is needed to evaluate the impact of different stages of endometriosis on IVF outcomes and to develop optimized management protocols for these patients. Full article
(This article belongs to the Section Perinatal and Neonatal Medicine)
Show Figures

Figure 1

9 pages, 963 KiB  
Commentary
Accuracy and Outcomes of Sentinel Lymph Node Biopsy in Male with Breast Cancer: A Narrative Review and Expert Opinion
by Calogero Cipolla, Vittorio Gebbia, Eleonora D’Agati, Martina Greco, Chiara Mesi, Giuseppa Scandurra, Daniela Sambataro and Maria Rosaria Valerio
Curr. Oncol. 2024, 31(12), 7566-7574; https://doi.org/10.3390/curroncol31120557 - 27 Nov 2024
Cited by 1 | Viewed by 1532
Abstract
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer cases. Sentinel lymph node biopsy (SLNB) has emerged as a less invasive alternative to axillary lymph node dissection (ALND) for axillary staging in breast cancer, offering [...] Read more.
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer cases. Sentinel lymph node biopsy (SLNB) has emerged as a less invasive alternative to axillary lymph node dissection (ALND) for axillary staging in breast cancer, offering reduced morbidity and comparable accuracy. However, the application of SLNB in MBC remains underexplored, with limited male-specific data and treatment protocols often extrapolated from female breast cancer studies. Available evidence suggests that SLNB in men demonstrates high diagnostic accuracy, with low false-negative rates and a high sentinel lymph node identification rate. Despite this, there is ongoing debate about its long-term impact on clinical outcomes, particularly for patients with sentinel node metastasis, where ALND may still provide superior survival outcomes in some cases. Predictive tools are being developed to identify better patients who may benefit from SLNB alone, potentially reducing the need for more invasive procedures. As the role of SLNB continues to evolve in MBC management, further prospective research is needed to refine its application and assess its long-term oncologic outcomes. Full article
Show Figures

Figure 1

15 pages, 5183 KiB  
Article
The Scintillation Counters of the High-Energy Particle Detector of the China Seismo-Electromagnetic (CSES-02) Satellite
by Simona Bartocci, Roberto Battiston, Stefania Beolè, Franco Benotto, Piero Cipollone, Silvia Coli, Andrea Contin, Marco Cristoforetti, Cinzia De Donato, Cristian De Santis, Andrea Di Luca, Floarea Dumitrache, Francesco Maria Follega, Simone Garrafa Botta, Giuseppe Gebbia, Roberto Iuppa, Alessandro Lega, Mauro Lolli, Giuseppe Masciantonio, Matteo Mergè, Marco Mese, Riccardo Nicolaidis, Francesco Nozzoli, Alberto Oliva, Giuseppe Osteria, Francesco Palma, Federico Palmonari, Beatrice Panico, Stefania Perciballi, Francesco Perfetto, Piergiorgio Picozza, Michele Pozzato, Ester Ricci, Marco Ricci, Sergio Bruno Ricciarini, Zouleikha Sahnoun, Umberto Savino, Valentina Scotti, Enrico Serra, Alessandro Sotgiu, Roberta Sparvoli, Pietro Ubertini, Veronica Vilona, Simona Zoffoli and Paolo Zucconadd Show full author list remove Hide full author list
Remote Sens. 2024, 16(21), 3982; https://doi.org/10.3390/rs16213982 - 26 Oct 2024
Cited by 3 | Viewed by 1400
Abstract
The High-Energy Particle Detector (HEPD-02) is one of the scientific payloads of the China Seismo-Electromagnetic Satellite (CSES-02). The HEPD-02’s main purpose is to characterize the particle environment in the Earth’s vicinity, identifying sudden changes in the fluxes and correlating them with solar and [...] Read more.
The High-Energy Particle Detector (HEPD-02) is one of the scientific payloads of the China Seismo-Electromagnetic Satellite (CSES-02). The HEPD-02’s main purpose is to characterize the particle environment in the Earth’s vicinity, identifying sudden changes in the fluxes and correlating them with solar and terrestrial phenomena. Additionally, HEPD-02 also has capabilities in detecting Gamma-Ray Bursts. At the core of HEPD-02, a tower of scintillation counters made of plastic and LYSO crystals is able to recognize electrons in the range between 3 and 100 MeV, protons and nuclei between 30 and 200 MeV/n. Plastic scintillators covering the calorimeter on five sides allow to reject particles entering from the top and not completely absorbed within its volume. In this work, the design of the HEPD-02 is reviewed in comparison to its predecessor, HEPD-01, highlighting the innovations of the new design. The design of each scintillation counter type has been fully validated through a campaign of prototype realization, testing, and characterization. The production of the scintillation counters, including the PMT selection process, is also discussed. Finally, the performance of the counters is compared with simulations, showing an agreement of within 20% with the expected performance, thereby meeting expectations. Full article
Show Figures

Graphical abstract

12 pages, 268 KiB  
Review
Comprehensive Axillary Management of Clinically Node-Positive (cN+) Breast Cancer Patients: A Narrative Review on Neoadjuvant Chemotherapy
by Calogero Cipolla, Vittorio Gebbia, Eleonora D’Agati, Martina Greco, Chiara Mesi, Giuseppa Scandurra and Maria Rosaria Valerio
Cancers 2024, 16(19), 3354; https://doi.org/10.3390/cancers16193354 - 30 Sep 2024
Cited by 3 | Viewed by 2843
Abstract
Background. In breast cancer (BC) patients, axillary management has undergone major improvements over the last few years, and efforts to identify the optimal strategy for the management of axillary surgery are still ongoing. Methods. In current clinical practice, women with clinically node-positive (cN+) [...] Read more.
Background. In breast cancer (BC) patients, axillary management has undergone major improvements over the last few years, and efforts to identify the optimal strategy for the management of axillary surgery are still ongoing. Methods. In current clinical practice, women with clinically node-positive (cN+) BC usually receive neoadjuvant chemotherapy (NACT) with the aim of reducing the extent of primary disease and, thus, allowing for axillary-conservative surgery. Remarkably, after NACT, up to one out of three patients achieves an axillary pathologic complete response, which, in turn, is associated with a more favorable prognosis than residual axillary disease. However, NACT is not without drawbacks, as NACT-associated inflammation can damage lymphatic vessels. Furthermore, varying degrees of response may occur in the axillary lymph nodes, increasing the false negative rate for sentinel biopsy. Results. At present, there is no consensus on the optimal approach in patients with cN+ BC undergoing NACT, although multidisciplinary management seems to be recommended. Conclusions. This narrative review provides a comprehensive overview of axillary management in cN+ BC patients undergoing NACT. It uses a multidisciplinary approach that encompasses the oncological management perspectives, as well as surgical and chemotherapeutic viewpoints. Full article
(This article belongs to the Section Clinical Research of Cancer)
14 pages, 584 KiB  
Review
Dysmorphic Uterus: More Questions than Answers
by Aikaterini Selntigia, Livia Pellegrini, Francesco Gebbia and Daniela Galliano
J. Clin. Med. 2024, 13(15), 4333; https://doi.org/10.3390/jcm13154333 - 25 Jul 2024
Viewed by 2449
Abstract
A T-shaped uterus is a rare uterine malformation that is classically associated with diethylstilbesterol (DES) exposure. Surprisingly, the prevalence of T- and Y-shaped uterus has increased in recent years despite the absence of a diagnostic consensus and a correlation with the reproductive outcomes [...] Read more.
A T-shaped uterus is a rare uterine malformation that is classically associated with diethylstilbesterol (DES) exposure. Surprisingly, the prevalence of T- and Y-shaped uterus has increased in recent years despite the absence of a diagnostic consensus and a correlation with the reproductive outcomes has been observed. A systematic electronic database search for all English-language studies published on reproductive outcomes associated with dysmorphic uteri over the past 10 years using PubMed, Google Scholar, and Scopus was performed. This uterine malformation is associated with impaired reproductive outcomes, including primary infertility, miscarriage, ectopic pregnancy, and preterm birth. Hysteroscopic metroplasty is a simple surgical procedure that could potentially improve outcomes in subfertile women, but the data are not robust. Studies reported significant improvements in implantation and pregnancy rates after corrective metroplasty in women undergoing in vitro fertilization. However, multicenter, prospective, randomized, and controlled trials are needed to validate these findings and to help define clear diagnostic criteria, surgical indications, and appropriate follow-up of reproductive outcomes after the procedure. Full article
Show Figures

Figure 1

22 pages, 523 KiB  
Review
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?
by Giuseppa Scandurra, Valentina Lombardo, Giuseppe Scibilia, Daniela Sambataro, Vittorio Gebbia, Paolo Scollo, Basilio Pecorino and Maria Rosaria Valerio
Cancers 2024, 16(13), 2466; https://doi.org/10.3390/cancers16132466 - 5 Jul 2024
Cited by 4 | Viewed by 4265
Abstract
Brain metastases (BM) pose a significant challenge in the management of HER2+ breast cancer since almost 50% of patients with HER2+ breast cancer develop brain tumors. The complex process of brain metastases involves genetic mutations, adaptations and mechanisms to overcome the blood–brain barrier. [...] Read more.
Brain metastases (BM) pose a significant challenge in the management of HER2+ breast cancer since almost 50% of patients with HER2+ breast cancer develop brain tumors. The complex process of brain metastases involves genetic mutations, adaptations and mechanisms to overcome the blood–brain barrier. While radiotherapy is still fundamental in local therapy, its use is associated with cognitive adverse effects and limited long-term control, necessitating the exploration of alternative treatments. Targeted therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and antibody–drug conjugates, offer promising options for HER2+ breast cancer patients with BM. Clinical trials have demonstrated the efficacy of these agents in controlling tumor growth and improving patient outcomes, posing the question of whether radiotherapy is always the unique choice in treating this cancer. Ongoing research into novel anti-HER2 antibodies and innovative combination therapies holds promise for advancing treatment outcomes and enhancing patient care in this clinical scenario. This narrative review provides a comprehensive overview of traditional medical treatments, molecularly targeted therapy and investigational agents in the management of HER2+ breast cancer with BM, highlighting the evolving landscape and potential future directions in treatment strategies to improve patient survival and quality of life. Full article
(This article belongs to the Special Issue New Approaches in Radiotherapy for Cancer)
Show Figures

Figure 1

9 pages, 495 KiB  
Article
The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach
by Dario Piazza, Federica Martorana, Annabella Curaba, Daniela Sambataro, Maria Rosaria Valerio, Alberto Firenze, Basilio Pecorino, Paolo Scollo, Vito Chiantera, Giuseppe Scibilia, Paolo Vigneri, Vittorio Gebbia and Giuseppa Scandurra
Curr. Oncol. 2024, 31(5), 2796-2804; https://doi.org/10.3390/curroncol31050212 - 14 May 2024
Cited by 4 | Viewed by 2672
Abstract
Introduction: In recent years, generative Artificial Intelligence models, such as ChatGPT, have increasingly been utilized in healthcare. Despite acknowledging the high potential of AI models in terms of quick access to sources and formulating responses to a clinical question, the results obtained using [...] Read more.
Introduction: In recent years, generative Artificial Intelligence models, such as ChatGPT, have increasingly been utilized in healthcare. Despite acknowledging the high potential of AI models in terms of quick access to sources and formulating responses to a clinical question, the results obtained using these models still require validation through comparison with established clinical guidelines. This study compares the responses of the AI model to eight clinical questions with the Italian Association of Medical Oncology (AIOM) guidelines for ovarian cancer. Materials and Methods: The authors used the Delphi method to evaluate responses from ChatGPT and the AIOM guidelines. An expert panel of healthcare professionals assessed responses based on clarity, consistency, comprehensiveness, usability, and quality using a five-point Likert scale. The GRADE methodology assessed the evidence quality and the recommendations’ strength. Results: A survey involving 14 physicians revealed that the AIOM guidelines consistently scored higher averages compared to the AI models, with a statistically significant difference. Post hoc tests showed that AIOM guidelines significantly differed from all AI models, with no significant difference among the AI models. Conclusions: While AI models can provide rapid responses, they must match established clinical guidelines regarding clarity, consistency, comprehensiveness, usability, and quality. These findings underscore the importance of relying on expert-developed guidelines in clinical decision-making and highlight potential areas for AI model improvement. Full article
Show Figures

Figure 1

8 pages, 480 KiB  
Perspective
Cancer: New Needs, New Models. Is It Time for a Community Oncologist? Another Brick in the Wall
by Paolo Tralongo, Vittorio Gebbia, Sebastiano Mercadante, Roberto Bordonaro, Francesco Ferraù, Sandro Barni and Alberto Firenze
Cancers 2021, 13(8), 1919; https://doi.org/10.3390/cancers13081919 - 16 Apr 2021
Cited by 11 | Viewed by 2273
Abstract
Over the last few decades, thanks to early detection, effective drugs, and personalized treatments, the natural history of cancer has radically changed. Thanks to these advances, we have observed how survival of cancer patients has increased, becoming an ever more important goal in [...] Read more.
Over the last few decades, thanks to early detection, effective drugs, and personalized treatments, the natural history of cancer has radically changed. Thanks to these advances, we have observed how survival of cancer patients has increased, becoming an ever more important goal in cancer care. Effective clinical governance of survivorship care is essential to ensure a successful transition between active and post-treatment life, identifying optimization of healthcare outcomes and quality of life for patients as the primary objectives. For these reasons, potential intervention models must consider these differences to rationalize the available resources, including economic aspects. In this perspective, analyzing the different models proposed in the literature to manage this type of patients, we focus on the possible role of the so-called “community oncologist”. As a trained health professional, also focused on longevity, he could represent the right management solution in all those “intermediate” clinical conditions that arise between the hospital specialist, frequently overworked, and the general practitioner, often biased by the lack of specific expertise. Full article
(This article belongs to the Special Issue Cancer Survivorship)
Show Figures

Figure 1

27 pages, 11934 KiB  
Article
Monitoring and Computation of the Volumes of Stockpiles of Bulk Material by Means of UAV Photogrammetric Surveying
by Grazia Tucci, Antonio Gebbia, Alessandro Conti, Lidia Fiorini and Claudio Lubello
Remote Sens. 2019, 11(12), 1471; https://doi.org/10.3390/rs11121471 - 21 Jun 2019
Cited by 56 | Viewed by 7506
Abstract
The monitoring and metric assessment of piles of natural or man-made materials plays a fundamental role in the production and management processes of multiple activities. Over time, the monitoring techniques have undergone an evolution linked to the progress of measure and data processing [...] Read more.
The monitoring and metric assessment of piles of natural or man-made materials plays a fundamental role in the production and management processes of multiple activities. Over time, the monitoring techniques have undergone an evolution linked to the progress of measure and data processing techniques; starting from classic topography to global navigation satellite system (GNSS) technologies up to the current survey systems like laser scanner and close-range photogrammetry. Last-generation 3D data management software allow for the processing of increasingly truer high-resolution 3D models. This study shows the results of a test for the monitoring and computing of stockpile volumes of material coming from the differentiated waste collection inserted in the recycling chain, performed by means of an unmanned aerial vehicle (UAV) photogrammetric survey and the generation of 3D models starting from point clouds. The test was carried out with two UAV flight sessions, with vertical and oblique camera configurations, and using a terrestrial laser scanner for measuring the ground control points and as ground truth for testing the two survey configurations. The computations of the volumes were carried out using two software and comparisons were made both with reference to the different survey configurations and to the computation software. Full article
Show Figures

Figure 1

Back to TopTop